Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could save eyes from melanoma surgery

NCT ID NCT05907954

Ongoing Disease control Sponsor: IDEAYA Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests darovasertib, a daily pill, in 160 people with uveal melanoma (a rare eye cancer). The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if the pill can shrink tumors enough to avoid eye removal, reduce radiation dose to healthy eye parts, and control small tumors. Researchers are also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Darovasertib (also called IDE196), a pill that blocks a protein involved in melanoma growth
What this could lead to
If it works, this could offer a way to treat uveal melanoma without removing the eye, possibly saving vision and reducing radiation damage.
What could go wrong
This is a mid-stage trial with 160 people, so results are not final. The drug may cause side effects or not shrink tumors enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plaque, Amyloid uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

  • Alfred Health

    Melbourne, Victoria, 3004, Australia

  • Charité - Universitätsmedizin Berlin

    Berlin, 12203, Germany

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, 00168, Italy

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • Institute Curie

    Paris, 75005, France

  • Leiden University Medical Center

    Leiden, 2333 ZA, Netherlands

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Moores Cancer Center

    La Jolla, California, 92093, United States

  • Northwell

    Manhasset, New York, 11030, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G2M9, Canada

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • St. Vincent's Health Sydney

    Sydney, New South Wales, 2010, Australia

  • Stanford Cancer Institute

    Palo Alto, California, 94305, United States

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan, 49546, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Miami

    Miami, Florida, 33146, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.